Please assess the completion status of the following clinical trial:

Trial Title: Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patients with clinically and histological or cytological confirmed newly diagnosed MM, that can be measured in two dimensions by a radiologic imaging study.~* Patients must be at least 18 years old and must be able to give written informed consent.~* Patients must be ambulatory (Karnofsky scale \> 70, or WHO-ECOG performance status 0,1, or 2) and in stable medical condition. The expected survival must be at least 4 months.~* Patients must have normal organ function and adequate bone marrow reserve: absolute neutrophil count \> 1.5 x 109/l, platelet count \> 100 x 109/l, and Hb \> 6.0 mmol/l.~* Positive DTH skin test (induration \> 2mm after 48 hrs) against at least one positive control antigen tetanus toxoid.~* Stable disease or response after chemotherapy.~* Availability of sufficient tumor material of the patient.~* Ability to return to the Erasmus MC for adequate follow-up as required by this protocol.~* Able to tolerate oral therapy~* No impairment of gastrointestinal (GI) function or GI disease that may affect or alter absorption of CTX (e.g., mal-absorption syndrome, history of total gastrectomy/significant small bowel resection)~* No history of allergic reactions (≥ grade 3 or 4) to compounds of similar chemical or biologic composition to CTX (i.e., alkylating agents)~* No known intolerance or hypersensitivity reaction to CTX~Exclusion criteria:~* Conditions that make the patient unfit for chemotherapy or progressive disease after 4 cycles of chemotherapy.~* Pleurodesis at the affected side before the pleural fluid is obtained.~* Medical or psychological impediment to probable compliance with the protocol.~* Patients on steroid (or other immunosuppressive agents) are excluded on the basis of potential immune suppression. Patients must have had 6 weeks of discontinuation and must stop of any such treatment during the time of the study.~* No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, superficial or in-situ cancer of the bladder or other cancer for which the patient has been disease-free for five years.~* Serious concomitant disease, no active infections. Patients with a history of autoimmune disease or organ allografts, or with active acute or chronic infection, including HIV (as determined by ELISA and confirmed by Western Blot) and viral hepatitis (as determined by HBsAg and Hepatitis C serology).~* Patients with serious intercurrent chronic or acute illness such as pulmonary (asthma or COPD) or cardiac (NYHA class III or IV) or hepatic disease or other illness considered by the study coordinator to constitute an unwarranted high risk for investigational DC treatment.~* Patients with a known allergy to shell fish (may contain KLH).~* Pregnant or lactating women.~* Patients with inadequate peripheral vein access to perform leukapheresis~* Concomitant participation in another clinical trial~* An organic brain syndrome or other significant psychiatric abnormality which would comprise the ability to give informed consent, and preclude participation in the full protocol and follow-up.~* Absence of assurance of compliance with the protocol. Lack of availability for follow-up assessment.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DC immunotherapy + CTX (Type: EXPERIMENTAL): Patients with mesothelioma who are fit enough to be treated with chemotherapy and enough tumor material was available are asked for participation in this study. After 4 cycles of Alimta chemotherapy, a leukapheresis is performed of which the monocytes are used for differentiation to DCs using different cytokines. The procedure to grow DCs in vitro and pulse them with tumor lysate is performed according to our earlier performed phase I study that was approved by our local ethics committee. Three doses of properly pulsed autologous DCs (MesoCancerVac) are then re-injected every two weeks. Patients will be treated with a low dose of CTX for seven day in a row the week before the 1st vaccination, the weeks in between the 2nd, and for one week after the 3rd vaccination.

Based on this trial design, predict the completion outcome and termination type (if applicable).